Gabexate, with the CAS number 39492-01-8, is a synthetic compound primarily recognized for its role as a protease inhibitor. It is classified as a serine protease inhibitor and is often utilized in clinical settings to manage conditions associated with excessive proteolytic activity, such as pancreatitis. Gabexate exhibits a high affinity for various serine proteases, including trypsin and thrombin, thereby modulating inflammatory responses and preventing tissue damage. The compound is typically administered intravenously and is known for its rapid onset of action. In terms of its chemical structure, Gabexate contains a carbon backbone with functional groups that facilitate its interaction with proteases. It is generally well-tolerated, although potential side effects may include allergic reactions or gastrointestinal disturbances. The pharmacokinetics of Gabexate indicate a relatively short half-life, necessitating careful dosing in therapeutic applications. Overall, Gabexate serves as an important pharmacological agent in the management of protease-related disorders.

Gabexate

39492-01-8: (E)-amino({6-[4-(ethoxycarbonyl)phenoxy]-6-oxohexyl}imino)methanaminium methanesulfonate, Benzoic acid, 4-((6-((aminoiminomethyl)amino)-1-oxohexyl)oxy)-, ethyl ester, Ethyl 4-({6-[(Diaminomethylidene)Amino]Hexanoyl}Oxy)Benzoate, Ethyl p-hydroxybenzoate 6-guanidinohexanoate, Gabexate [INN], Gabexato, Gabexato [INN-Spanish], Gabexatum, Gabexatum [INN-Latin], Unii-4V7M9137X9, p-Carbethoxyphenyl ε-guanidineocaproate, p-Carbethoxyphenyl ε-guanidinocaproate, Gabexate,  Gabexate

Gabexate is a protease inhibitor that is used to treat acute pancreatitis. It inhibits the activity of trypsin and other proteases, which are enzymes that break down proteins in the body. Gabexate mesylate inhibits the activity of these enzymes, thereby reducing inflammation and improving digestion. It has been shown to be effective in treating syncytial virus infection, as well as acute pancreatitis. Gabexate also has inhibitory properties against injury of the pancreas, which may be due to its inhibition of protein synthesis, leading to less cell death. Gabexate mesylate can cause drug interactions with drugs such as erythromycin or ciprofloxacin because it is a substrate for CYP3A4 and P-glycoprotein.

CAS 39492-01-8: Gabexate

Gabexate

Ref: 3D-PBA49201

Gabexate Mesylate

Ref: 3B-G0464